Clinical Trials Directory

Trials / Completed

CompletedNCT01515124

The Women In Steady Exercise Research (WISER) Survivor Trial

The Women In Steady Exercise Research (WISER) Survivor Trial & Cost of Illness and Cost Effectiveness of Alternative Management Strategies

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
450 (actual)
Sponsor
Milton S. Hershey Medical Center · Academic / Other
Sex
Female
Age
80 Years
Healthy volunteers
Accepted

Summary

WISER Survivor is a one year weight loss and exercise study for sedentary breast cancer survivors who are overweight or obese with breast cancer related lymphedema. There will be four groups in this trial: exercise only, weight loss only, exercise and weight-loss combined, and a control group. The primary purpose of this study is to test the effects of these interventions on clinical lymphedema outcomes. Secondary outcomes include weight loss, breast cancer related biomarkers, and quality of life. To the extent that funding will be available, participants will be followed long term to examine effects on recurrence and mortality.

Conditions

Interventions

TypeNameDescription
BEHAVIORALExercise InterventionThe Exercise Intervention combines the twice-weekly weight-lifting intervention from PAL with the 180 minutes of weekly aerobic exercise from the recently completed WISER trial and the ongoing WISER Sister Trial. Women will be trained by certified fitness professionals in both the PAL weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions.
BEHAVIORALWeight Loss InterventionThe Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day.

Timeline

Start date
2012-01-01
Primary completion
2016-05-01
Completion
2016-05-01
First posted
2012-01-23
Last updated
2022-10-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01515124. Inclusion in this directory is not an endorsement.